Prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: A cross‐sectional study

OBJECTIVE: To explored the prognostic value of pretreatment serum fibrinogen level in young patients with small cell lung cancer (SCLC). METHODS: The concentrations of serum fibrinogen of 183 young (<50 years old) SCLC patients were measured. The association of baseline serum fibrinogen level and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Juncai, Tian, Huohuan, Yang, Mengzhu, Yang, Linhui, Liu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439336/
https://www.ncbi.nlm.nih.gov/pubmed/37599658
http://dx.doi.org/10.1002/hsr2.1507
_version_ 1785092920789958656
author Tian, Juncai
Tian, Huohuan
Yang, Mengzhu
Yang, Linhui
Liu, Dan
author_facet Tian, Juncai
Tian, Huohuan
Yang, Mengzhu
Yang, Linhui
Liu, Dan
author_sort Tian, Juncai
collection PubMed
description OBJECTIVE: To explored the prognostic value of pretreatment serum fibrinogen level in young patients with small cell lung cancer (SCLC). METHODS: The concentrations of serum fibrinogen of 183 young (<50 years old) SCLC patients were measured. The association of baseline serum fibrinogen level and clinical outcome was analyzed by survival analysis. RESULTS: Hyperfibrinogenemia was significantly associated with American Veterans Administration Lung Study Group stage and surgery treatment. The survival analysis indicated that patients with hypefibrinogenemia had worse outcome than patients with normal fibrinogen. Pretreatment serum fibrinogen level was identified as a worse independent survival predictor in young SCLC. The hazard ratio was 1.420 (95% confidence interval: 1.035−1.947). CONCLUSIONS: Pretreatment serum fibrinogen is independent associated with overall survival in patients with young SCLC.
format Online
Article
Text
id pubmed-10439336
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104393362023-08-20 Prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: A cross‐sectional study Tian, Juncai Tian, Huohuan Yang, Mengzhu Yang, Linhui Liu, Dan Health Sci Rep Original Research OBJECTIVE: To explored the prognostic value of pretreatment serum fibrinogen level in young patients with small cell lung cancer (SCLC). METHODS: The concentrations of serum fibrinogen of 183 young (<50 years old) SCLC patients were measured. The association of baseline serum fibrinogen level and clinical outcome was analyzed by survival analysis. RESULTS: Hyperfibrinogenemia was significantly associated with American Veterans Administration Lung Study Group stage and surgery treatment. The survival analysis indicated that patients with hypefibrinogenemia had worse outcome than patients with normal fibrinogen. Pretreatment serum fibrinogen level was identified as a worse independent survival predictor in young SCLC. The hazard ratio was 1.420 (95% confidence interval: 1.035−1.947). CONCLUSIONS: Pretreatment serum fibrinogen is independent associated with overall survival in patients with young SCLC. John Wiley and Sons Inc. 2023-08-18 /pmc/articles/PMC10439336/ /pubmed/37599658 http://dx.doi.org/10.1002/hsr2.1507 Text en © 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Tian, Juncai
Tian, Huohuan
Yang, Mengzhu
Yang, Linhui
Liu, Dan
Prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: A cross‐sectional study
title Prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: A cross‐sectional study
title_full Prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: A cross‐sectional study
title_fullStr Prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: A cross‐sectional study
title_full_unstemmed Prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: A cross‐sectional study
title_short Prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: A cross‐sectional study
title_sort prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: a cross‐sectional study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439336/
https://www.ncbi.nlm.nih.gov/pubmed/37599658
http://dx.doi.org/10.1002/hsr2.1507
work_keys_str_mv AT tianjuncai prognosticvalueofpretreatmentserumfibrinogeninyoungpatientswithsmallcelllungcanceracrosssectionalstudy
AT tianhuohuan prognosticvalueofpretreatmentserumfibrinogeninyoungpatientswithsmallcelllungcanceracrosssectionalstudy
AT yangmengzhu prognosticvalueofpretreatmentserumfibrinogeninyoungpatientswithsmallcelllungcanceracrosssectionalstudy
AT yanglinhui prognosticvalueofpretreatmentserumfibrinogeninyoungpatientswithsmallcelllungcanceracrosssectionalstudy
AT liudan prognosticvalueofpretreatmentserumfibrinogeninyoungpatientswithsmallcelllungcanceracrosssectionalstudy

Ejemplares similares